Takeda to divest select assets in China to Hasten Biopharmaceutic for $322 mn
The portfolio to be divested to Hasten includes cardiovascular and metabolism products sold in mainland China
Recover your password.
A password will be e-mailed to you.
Recover your password.
A password will be e-mailed to you.